FDA Guidance On Peripheral Neuropathy Drugs In The Works
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency is holding a public workshop to discuss therapeutic targets and clinical trial design for disease-modifying agents to treat peripheral neuropathy; many products in recent development have faced challenges.
You may also be interested in...
Trial Designs For Non-Cystic Fibrosis Bronchiectasis May Need Refinement
FDA public workshop will consider the design of clinical studies testing antibacterial drugs to treat lung damage caused by recurrent infections.
Gastroenterology Endpoints To Get Four-Day Series Of FDA Workshops
One day each will be devoted to eosinophilic esophagitis, pediatric and adult inflammatory bowel disease, and parenteral nutrition-associated liver disease, Sept. 19, 20, 21 and 24, in that order.
Pfizer’s Pride-And-Joy Pain Drug Lyrica Slips In Two New Phase III Trials
One failed study tested Lyrica in a subset of difficult-to-treat patients in the approved indication of diabetic neuropathy, while another explored its use in neuropathic pain related to HIV.